Navigation Links
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Date:2/16/2011

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as part of the Halozyme-Roche collaboration. Initiation of the clinical trial has triggered a milestone payment of $5 million to Halozyme. MabThera is approved to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) using different induction and maintenance treatments that are currently given intravenously (IV).

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The start of this Phase 3 subcutaneous MabThera trial in patients with follicular NHL signifies another major achievement for the Halozyme-Roche partnership, and represents the second Roche target to begin a pivotal trial. I congratulate the team on this important accomplishment," said Gregory Frost, Ph.D., Halozyme's president and CEO. "MabThera is the standard of ca
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
2. Halozyme Receives $5.5 Million Payment From Baxter
3. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
4. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
5. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics to Host Research Day for Investors and Analysts
8. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
9. Halozyme Therapeutics to Present at Upcoming Investor Conferences
10. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... that provides innovative genetic analysis solutions, and Mayo ... laboratory services in the United States ... testing patents and applications. "We have great ... patient care, and we welcome the opportunity to partner ...
(Date:7/29/2014)... , July 29, 2014  The Society for ... and updated program for the 9 th ... 2014 in Amelia Island , Florida.  The ... investigators remains unchanged, however, the topics and format ... networking opportunity among all stakeholders with a continued ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... Rockville, MD (PRWEB) July 29, 2014 ... (ITI), a vaccine pioneer in the biotechnology industry, ... firm Newport Coast Securities, Inc. to explore financing ... commercializing LAMP-vax technology, a breakthrough vaccine platform with ... immunotherapy market. The company exclusively licensed the well-established ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... , ... • chemiluminescence , , ... enzymes exist, their activities having wide-ranging regulatory responses. Many kinases ... as inflammation and cancer, so identifying modulators of kinase and ...
... , , , ... Hancock, Elaine Adie, Molly Price-Jones, Stephen Game & Stuart Swinburne , ... Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA England, ... , As high throughput imaging systems, analysis ...
... , ... The Maynard Centre, Cardiff, UK , ... and the development of high-throughput image analysis platforms such as the IN ... we describe the application of two stable cell lines expressing green fluorescent ...
Cached Biology Technology:Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 2Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 3Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 2siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 3siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 5siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 6siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 7
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... Aarhus University researchers have developed an easier method ... strengthen the work involved in diagnosing diseases. , ... provides a strong partnership that can be used ... conjugates which tag proteins with DNA ... sensitive detection and visualisation of biological material. The ...
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
Breaking Biology News(10 mins):Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... The University of Houston department of health and human ... Life (SL) thanks to grants from the UH Faculty ... of the University of Southern California-Annenberg School for Communication. ... ground in Second Life for the benefit of our ...
... The life expectancy for patients with human immunodeficiency ... since the late 1990s thanks to advancements in antiretroviral ... at Birmingham (UAB) and Simon Fraser University in Vancouver, ... nearly 40 percent drop in AIDS deaths among 43,355 ...
... on the brain" must have shunts implanted to drain the ... While shunts do their job well, the rate of ... of reasons, which requires putting the child through another surgery ... potential additional neurological complications and an increased risk of death. ...
Cached Biology News:Second Life a first for UH department of health and human performance 2Anti-HIV therapy boosts life expectancy more than 13 years 2Antimicrobial sutures reduce infections in brain shunt surgery, study finds 2
... includes 1. Scanning of gel(s) 2. ... tryptic in-gel digestion and peptide extraction ... 5. Acquisition of PMF (Peptide Mass ... TOF/TOF) 6. Acquisition of PFF (Peptide ...
... Nucleic acid hybridization Preparation ... mg BSA, 50 mg ficoll ... with 5 ml of water ... for molecular biology Density: 1.00 ...
... ImageXpress 5000A automated cellular imaging and analysis ... system designed specifically for rapid acquisition and ... cell-based screening. ImageXpress is fast. Scanning ... (1280 x 1024 pixels), with two fluorescence ...
... Antibody Capture Kit eliminates ... optimization steps typically required ... This kit enables the ... multiple antigens based on ...
Biology Products: